第一部分 奋斗历程 1
于金明院士简历 3
从农民到院士——记中国工程院院士、山东省肿瘤医院院长于金明 5
第二部分 学术贡献 21
一、于金明院士的主要学术成就与学术思想 23
二、于金明院士的主要学术论文 25
ERCC1 Expression and Tumor Regression Predict Survival in Esophageal Squamous Cell Carcinoma Patients Receiving Combined Trimodality Therapy 25
Repopulation of Tumor Cells During Fractionated Radiotherapy and Detection Methods（Review） 33
Effect of Celecoxib on Inhibiting Tumor Repopulation During Radiotherapy in Human FaDu Squamous Cell Carcinoma 40
Prognostic Significance of Epidermal Growth Factor Receptor in Locally Advanced Esophageal Squamous Cell Carcinoma for Patients Receiving Chemoradiotherapy 49
Prognostic Value of 3’-Deoxy-3’-18F-Fluorothymidine（[18F] FLT PET） in Patients with Recurrent Malignant gliomas 55
Progress of Radiation Oncology：Known and Unknown 64
Human Epidermal Growth Factor Receptor-2 Expression in Locally Advanced Rectal Cancer：Association with Response to Neoadjuvant Therapy and Prognosis 71
Changes in Functional Lung Regions During the Course of Radiation Therapy and Their Potential Impact on Lung Dosimetry for Non-Small Cell Lung Cancer 80
Prediction of Response to Preoperative Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer 87
Involved-Field Irradiation in Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma 101
A PhaseⅠStudy of Concurrent Chemotherapy and Thoracic Radiotherapy with Oral Epigallocatechin-3-Gallate Protection in Patients with Locally Advanced Stage Ⅲ Non-Small-Cell Lung Cancer 108
Reversion of Erlotinib-Acquired Resistance Twice by Chemotherapy A Case Report 115
Hypoxia Imaging with 18F-Fluoroerythronitroimidazole Integrated PET/CT and Immunohistochemical Studies in Non-Small Cell Lung Cancer 121
New Strategy for Monitoring Targeted Therapy：Molecular Imaging 129
Cetuximab in Combination with Chemoradiotherapy in Chinese Patients with Non-Resectable，Locally Advanced Esophageal Squamous Cell Carcinoma：A Prospective，Multicenter Phase Ⅱ Trail 140
Mediastinal lymph Nodes Staging by18F-FDG PET/CT for Early Stage Non-Small Cell Lung Cancer：A Multicenter Study 147
Implementation of Hypoxia Measurement Into Lung Cancer Therapy 154
Effect of Recombinant Human Endostatin on Radiosensitivity in Patients with Non-Small-Cell Lung Cancer 160
Imaging Proliferation of 18F-FLT PET/CT Correlated with the Expression of Microvessel Density of Tumour Tissue in Non-Small-Cell Lung Cancer 168
Applications of IMAT in Cervical Esophageal Cancer Radiotherapy：a Comparison with Fixed-Field IMRT in Dosimetry And Implementation 176
Molecular Imaging with11C-PD153035 PET/CT Predicts Survival in Non-Small Cell Lung Cancer Treated with EGFR-TKI： A Pilot Study 185
Linear Correlation Between Patient Survival and Decreased Percentage of Tumor[18F] Fluorodeoxyglucose Uptake for Late-Course Accelerated Hyperfractionated Radiotherapy for Esophageal Cancer 194
Lipiodol：a Potential Direct Surrogate for Cone-Beam Computed Tomography Image Guidance in Radiotherapy of Liver Tumor 202
Noninvasive Evaluation of Microscopic Tumor Extensions Using Standardized Uptake Value and Metabolic Tumor Volume in Non-Small-Cell Lung Cancer 211
Measuring Tumor Hypoxia with 18F-FETNIM PET in Esophageal Squamous Cell Carcinoma：a Pilot Clinical Study 219
Value of Dual-Time-Point FDG PET/CT for Mediastinal Nodal Staging in Non-Small-Cell Lung Cancer Patients with Lung Comorbidity 227
Prediction of the Outcome of Definitive Chemoradiation by Decrease in F-18 FDG Uptake in Nonsurgical Esophageal Squamous Cell Cancer 234
Prognostic Value of18F-FDG PET/CT Before and After Radiotherapy for Locally Advanced Nasopharyngeal Carcinoma 244
Inhibitory Effect of Radiotherapy Combined with Weekly Recombinant Human Endostatin on the Human Pulmonary Adenocarcinoma A549 Xenografts in Nude Mice 251
Measuring Tumor Cell Proliferation with 18F-FLT PET During Radiotherapy of Esophageal Squamous Cell Carcinoma：A Pilot Clinical Study 260
Imaging of Proliferation with 18F-FLT PET/CT Versus 18F-FDG PET/CT in Non-Small-Cell Lung Cancer 268
Relationship Between Primary Lesion FDG Uptake and Clinical Stage at PET-CT for Non-Small Cell Lung Cancer Patients：An Observation 276
Comparison of Tumor Volumes as Determined by Pathologic Examination and FDG-PET/CT Images of NON-SMALL-Cell Lung Cancer： a Pilot Study 282
Relationship Between Primary Tumor Fluorodeoxyglucose Uptake and Nodal or Distant Metastases at Presentation in T1 Stage Non-Small Cell Lung Cancer 290
Using18F-Fluorodeoxyglucose Positron Emission Tomography to Estimate the Length of Gross Tumor in Patients with Squamous Cell Carcinoma of the Esophagus 295
Comparison of 18F-Fluorothymidine and18F-Fluorodeoxyglucose PET/CT in Delineating Gross Tumor Volume by Optimal Threshold in Patients with Squamous Cell Carcinoma of Thoracic Esophagus 302
PET-Based Biodistribution and Radiation Dosimetry of Epidermal Growth Factor Receptor-Selective Tracer11C-PD153035 in Humans 311
Molecular Imaging of EGFR：It’s Time to Go Beyond Receptor Expression 318
Effects of Lentivirus-Mediated HIF-1α Knockdown on Hypoxia-Related Cisplatin Resistance and Their Dependence on p53 Status in Fibrosarcoma Cells 323
Value of PET/CT Versus Enhanced CT for Locoregional Lymph Nodes in Non-Small Cell Lung Cance 331
Assessment of11C-labeled-4-N-（3-bromoanilino）-6，7-Dimethoxyquinazoline as a Positron Emission Tomography Agent to Monitor Epidermal Growth Factor Receptor Expression 340
Determining Optimal Clinical Target Volume Margins on The Basis of Microscopic Extracapsular Extension of Metastatic Nodes in Patients with NON-SMALL-CELL Lung Cancer 347
Diagnostic and Prognostic Value of18F-FDG PET/CT for Patients with Suspected Recurrence from Squamous Cell Carcinoma of the Esophagus 357
Additional Value of PET /CT over PET in Assessment of Locoregional Lymph Nodes in Thoracic Esophageal Squamous Cell Cancer 366
The Pattern of Lymphatic Metastasis of Breast Cancer and Its Influence on The Delineation of Radiation Fields 372
Flow Cytometric DNA Content and Clinical Outcome in Patients with Non-Small Cell Lung Cancer Given Postoperative Radiation Therapy1 378
DNA Ploidy Analysis of Effectiveness of Radiation Therapy for Cervical Carcinoma 383
Flow Cytometric Analysis DNA Content in Esophageal Carcinoma Correlation with Histologic and Clinical Features 387
影像技术在放射肿瘤学中的应用 390
图像引导放射治疗研究及其发展 394
生物靶区与生物适形放疗研究进展 397
Ⅲ期非小细胞肺癌累及野照射的可行性研究 402
局部晚期非小细胞肺癌累及野照射的研究进展 408
调强放射治疗的临床应用现状与存在的问题 415
功能性影像确定肿瘤放射治疗生物靶区的研究进展 420
18F-脱氧葡萄糖PET用于制定肿瘤放射治疗计划研究进展 426
非小细胞肺癌术前肺门纵隔淋巴结CT检查和术后病理结果比较的研究 432
二十一世纪的放射肿瘤学 436
调强放射治疗研究进展 443
乳腺癌淋巴结转移规律对术后放射治疗设野的影响 450
第三部分 治学之道 455
精确放疗，精确到细胞——访中华医学会放射肿瘤学分会主任委员、山东省肿瘤医院院长、博士生导师于金明教授 457
科学是值得一生追求的事业——记全国人大代表、山东省肿瘤医院院长于金明 460
大院士讲小故事 做人做事做学问——听工程院院士、山东省肿瘤医院院长于金明“如何做个好医生”的公开课 462
于金明：精确定位人生 466
中国工程院院士于金明：将“精确”进行到底 472
一个人与三个不同角色——访山东省肿瘤医院院长于金明 476
第四部分 大师风范 481
我的老师于金明 483
传道授业，润物无声 485
德医双馨——我的导师于金明 487
以大任为己任——我眼中的于金明导师 488
孜孜不倦求真知 拳拳之情育桃李——记于金明院士师门下的点滴感悟 490
中国工程院院士于金明：用心灵与学生对话，杏林人生满芬芳 493
谆谆教诲 无私奉献——记我的恩师于金明院士 495
真的种子，善的信使，美的旗帜——学生眼中的于金明院士 497
“草根院士”的大医之路——我心目中的于金明院长 500
我心目中的于院长 502
大爱暖边疆——记我的导师于金明院士 504
大医精诚 大爱无声——致中国工程院院士于金明 506
大医精诚·杏林春暖——我心目中的恩师于金明院士 509
点点滴滴是党恩 511
故乡的小河 512
第五部分 社会影响 513
于金明：和肿瘤细胞打一场“精确”战争 515
走近肿瘤放疗专家于金明教授 517
于金明：肿瘤放疗命中“靶心” 521
肿瘤斗士的老区情结——记中国工程院院士、山东省肿瘤医院院长于金明 523
我是来交作业的——记校友于金明院士 527
放疗：从未知到已知再到未知 530
于金明：将精确进行到底 532
于金明开启肿瘤治疗“精确放疗”时代 535
报答——2010年度山东省科学技术最高奖获得者于金明 536
为学科成长规划路径——山东省肿瘤医院内涵建设实践（上） 537
为“后生”成长培育沃土——山东省肿瘤医院内涵建设实践（下） 540
执大道而建奇功 543
于金明说防癌：减少环境污染是根本 547
于金明：守望麦田的医学家 548
于金明，“精确”对战肿瘤 553
“谈癌色变”大可不必——专访中国工程院院士于金明 557
医疗改革 任重道远——访全国人大代表 山东省肿瘤防治研究院院长于金明 560
防癌、抗癌需要全社会努力——中国工程院院士、山东省肿瘤医院院长于金明谈癌症的预防和治疗 563
第六部分 人生风采 567
成长历程 569
勤奋工作 572
学术交流 575
重要时刻 577
社会责任 579